GC Biopharma establishes mRNA production facility in Hwasun, Korea

December 01, 2023 07:31 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
  • Completed the construction of a GMP pilot plant in its Hwasun production plant in Jeollanam-do, Korea
  • Plans to expand its domain from vaccine development to the field of rare disease treatments by proactively securing mRNA platforms

YONGIN, South Korea, Dec. 1, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company (CEO, Eun-Chul Huh), announced on November 30th that it has completed the construction mRNA (messenger ribonucleic acid) production facility in its own vaccine production plant in Hwasun, Jeollanam-do, Korea, and will soon start the operation.

The production facility is a GMP pilot plant that will support the company's strategy to internalize various mRNA-related technologies while continuously building up related capabilities.

The new facility offers an "all-in-one" production capability that accommodates all phases of mRNA production. It can, therefore, significantly reduce the contamination risk of transfer and allows prompt production response. In addition, the pilot plant has a "single-use" production facility that will reduce the cross-contamination risk and enable the production of multiple products at once.

Taking the mRNA as one of its new drug development platforms, GC Biopharma has been putting efforts in this area by signing the lipid nanoparticle (LNP) development and option agreement with Acuitas Therapeutics last year and establishing a new mRNA-LNP platform this year. It is now actively making R&D efforts to advance into a clinical stage. Currently, this platform is being applied to develop treatment for SSADHD, one of the rare diseases, as well as mRNA influenza vaccine.

Based on the technologies and capabilities it would accumulate in the new mRNA production facility by testing the effectiveness and safety of various vaccines and treatment candidates, the company is planning to produce drugs for clinical trials in the GMP pilot plant with a roadmap to move on to commercialization and further to CMO business.

Jae Uk Jeong, Head of R&D at GC Biopharma said, "Construction of the new production facility was a part of our project to move ahead in securing the mRNA platform technology. We expect the facility to be widely used in various joint R&D and responses to any future pandemics."

About GC Biopharma

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein and vaccine product manufacturers globally and has been dedicated to quality healthcare solutions for more than half a century.

This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.

GC Biopharma Contacts (Media)
Seunghyun Baek
[email protected]
Sohee Kim
[email protected]
Yelin Jun
[email protected]


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.